Since dual-targeting tGLI1 and GP130 suppresses metastatic burden and prolongs MFS in vivo (Figure 7B,C), we next wanted to examine the clinical relevance of tGLI1 and IL-6/IL-6R/GP130 in breast cancer metastasis using publicly available patient datasets. This evidence concerns the gene IL6R and breast carcinoma.